British Journal of Clinical PharmacologyVolume 74, Issue 1 p. 224-225 Free Access Erratum This article corrects the following: Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System Elena Ramirez, Olga Laosa, Pedro Guerra, Blanca Duque, Beatriz Mosquera, Alberto M. Borobia, Suhua H. Lei, Antonio J. Carcas, Jesus Frias, Volume 70Issue 5British Journal of Clinical Pharmacology pages: 694-702 First Published online: July 26, 2010 First published: 11 June 2012 https://doi.org/10.1111/j.1365-2125.2012.04349.xCitations: 2AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Ramirez E, Laosa O, Guerra P, Duque B, Mosquera B, Borobia AM, Lei SH, Carcas AJ, Frias J. Br J Clin Pharmacol 2010; 70: 694–702. In [1], the article states that loratadine is a BCS Class I drug (in Table 1, column 1, line 10; Table 4, column 1, line 14; and page 698, column 1, line 4). Data were obtained from the Therapeutic System Research Laboratories website (at http://www.tsrlinc.com/services/bcs/search.cfm). The new website of Therapeutic System Research Laboratories at http://69.20.123.154/services/bcs/results.cfm yields a page displaying loratadine as Class II and the metabolite desloratadine as Class I (last accessed March 21, 2012). The corrected versions of Table 1 and 4 and the sentence on page 698 are published below. Table 1. Biopharmaceutics Classification System (BCS) of active substances (number of studies) Table 4. Results of non-BE formulations (study number of subjects, retrospective sample size calculation) classified by BCS active substances for maximum observed plasma concentration (Cmax) and area under the concentration-time curve (AUC) In one case (sildenafil) the CVIntrasubject was higher than predicted (Group A2 Table 4). REFERENCE Ramirez E, Laosa O, Guerra P, Duque B, Mosquera B, Borobia AM, Lei SH, Carcas AJ, Frias J. Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System. Br J Clin Pharmacol 2010; 70: 694– 702. Citing Literature Volume74, Issue1July 2012Pages 224-225 ReferencesRelatedInformation